Genetic testing provides answers
Invitae’s chromosomal microarray analysis (CMA) for pregnancy loss is DNA-based and delivers results in more than 92.4%1 of cases in as soon as 10-12 days, on average. No cell culture is required.
Uncover the cause of recurrent miscarriage
Approximately one in five clinically recognized pregnancies ends in miscarriage. Of first-trimester pregnancy losses, more than 50% are due to a fetal chromosomal abnormality.
Find answers about an intrauterine fetal demise (IUFD) or stillbirth
Invitae testing can help determine the cause of second and third-trimester loss to give patients answers to their hardest question: why.
Benefits of microarray testing
-
Better suited for the analysis of pregnancy loss tissue
-
Can be performed on formalin-fixed, paraffin-embedded samples
-
No cell culture required
-
Simultaneously detects maternal cell contamination without a maternal blood sample
-
Readily detects triploidy and molar pregnancies
-
Covers more bases to help prevent unnecessary testing
-
Allows for appropriate medical management and recurrence risk counseling
Microarray vs. karyotyping
| Invitae’s microarray | Karyotyping | |
| Percentage of cases where results are obtained | >92.4%1 | 60-80%1-3 |
| Cell culture required | No (DNA-based) | Yes (frequent cell culture failure) |
| Can be performed on formalin-fixed, paraffin-embedded samples? | Yes | No |
| Detects submicroscopic gains and losses | Yes | No |
| Detects submicroscopic imbalances and molar pregnancy | Yes | No |
| Detects maternal cell contamination | Yes | No |
| Turnaround time | 10-12 days on average | ≥2 weeks (if culture is successful) |
Why choose Invitae’s microarray analysis for testing pregnancy loss?
Flexible sample collection options
In cases where collecting a fresh tissue sample is not an option, Invitae accepts formalin-fixed, paraffin-embedded samples.
Superior coverage
Invitae technology provides superior, clinically focused, genome-wide coverage.
Comprehensive reports
Invitae provides references to assist in patient counseling and links to tools for evaluating results.
Expert interpretation
Invitae’s laboratory directors have decades of experience in interpreting microarray results and can assist you in understanding complex results.
The Invitae advantage
We make billing simple, so you can focus on your patients
Invitae is proud to be in-network for more than 270 million patients, and to offer a financial assistance program for patients without coverage.
Hands-on clinical support for clinicians and patients
Invitae’s board-certified genetic counselors provide peer support for clinicians and post-test counseling for parents at no additional charge.
Get started
Follow these easy steps to get started with Invitae:
|
|
Request a free specimen collection kit online. |
|
|
Order a test using a paper test requisition form.
|
|
|
Receive a comprehensive results report
|
Resources
Additional tests for patients across all reproductive stages
Invitae offers a comprehensive test menu that delivers actionable insights for all your patients, whether they are considering pregnancy or already pregnant.
Proactive cancer screening
More than 9% of healthy adults have a genetic risk of developing cancer.
Cancer screening can offer healthy adults an opportunity to understand their DNA, assess heritable cancer risk, and take proactive action if necessary.
Carrier screening
80% of children born with genetic disorders have no family history.
The American College of Obstetricians and Gynecologists (ACOG) recommends offering carrier screening to all patients of reproductive age, either before or during pregnancy.
Non-invasive prenatal screening (NIPS)
Invitae NIPS can be performed as early as 10 weeks gestational age.
Invitae NIPS offers an industry-leading low test failure rate of <0.1% and offers 99% sensitivity and specificity for most chromosomes screened.
References:
- Sahoo T et al. Comprehensive genetic analysis of pregnancy loss by chromosomal microarrays: outcomes, benefits, and challenges. Genet Med. 2017;19(1):83-9.
- Warren JE et al. Array comparative genomic hybridization for genetic evaluation of fetal loss between 10 and 20 weeks of gestation. Obstet Gynecol. 2009;114(5):1093-102.
- Ljunger E et al. Chromosomal anomalies in first-trimester miscarriages. Acta Obstet Gynecol Scand. 2005;84:1103-7.
